狼牙棒
医学
危险系数
内科学
心肌梗塞
糖尿病
移植
肾移植
冲程(发动机)
心脏病学
经皮冠状动脉介入治疗
置信区间
内分泌学
机械工程
工程类
作者
Petros Yiannoullou,Angela Summers,Shu C. Goh,Catherine Fullwood,Hussein A. Khambalia,Zia M. Moinuddin,Iestyn M. Shapey,Josephine H. Naish,Chris Miller,Titus Augustine,Martin K. Rutter,David van Dellen
出处
期刊:Diabetes Care
[American Diabetes Association]
日期:2019-02-14
卷期号:42 (4): 665-673
被引量:25
摘要
OBJECTIVE: People with type 1 diabetes and kidney failure have an increased risk for major adverse cardiovascular events (MACE). Simultaneous pancreas and kidney transplantation (SPKT) improves survival, but the long-term risk for MACE is uncertain. RESEARCH DESIGN AND METHODS: We assessed the frequency and risk factors for MACE (defined as fatal cardiovascular disease and nonfatal myocardial infarction or stroke) and related nonfatal MACE to allograft failure in SPKT recipients with type 1 diabetes who underwent transplantation between 2001 and 2015 in the U.K. In a subgroup, we related a pretransplant cardiovascular risk score to MACE. RESULTS: During 5 years of follow-up, 133 of 1,699 SPKT recipients (7.8%) experienced a MACE. In covariate-adjusted models, age (hazard ratio 1.04 per year [95% CI 1.01-1.07]), prior myocardial infarction (2.6 [1.3-5.0]), stroke (2.3 [1.2-4.7]), amputation (2.0 [1.02-3.7]), donor history of hypertension (1.8 [1.05-3.2]), and waiting time (1.02 per month [1.0-1.04]) were significant predictors. Nonfatal MACE predicted subsequent allograft failure (renal 1.6 [1.06-2.6]; pancreas 1.7 [1.09-2.6]). In the subgroup, the pretransplant cardiovascular risk score predicted MACE (1.04 per 1% increment [1.02-1.06]). CONCLUSIONS: We report a high rate of MACE in SPKT recipients. There are a number of variables that predict MACE, while nonfatal MACE increase the risk of subsequent allograft failure. It may be beneficial that organs from hypertensive donors are matched to recipients with lower cardiovascular risk. Pretransplant cardiovascular risk scoring may help to identify patients who would benefit from risk factor optimization or alternative transplant therapies and warrants validation nationally.
科研通智能强力驱动
Strongly Powered by AbleSci AI